Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 16/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | SCN4A | P35499 | 1/20 | 0.74 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.74 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.74 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamazepine SCHEMBL6477112 | 0.86 | LMNA (1.00) | P2RX4LMNATSHRMAPK1SCN4A | |
| Carbamazepine SCHEMBL29360181 | 0.86 | LMNA (1.00) | P2RX4LMNATSHRMAPK1SCN4A | |
| Carbamazepine SCHEMBL21639 | 0.86 | LMNA (1.00) | P2RX4LMNATSHRMAPK1SCN4A | |
| Carbamazepine SCHEMBL31685158 | 0.86 | LMNA (1.00) | P2RX4LMNATSHRMAPK1SCN4A | |
| Carbamazepine SCHEMBL29433237 | 0.86 | LMNA (1.00) | P2RX4LMNATSHRMAPK1SCN4A | |
| Carbamazepine SCHEMBL5382102 | 0.84 | LMNA (0.96) | P2RX4LMNATSHRMAPK1SCN4A | |
| Carbamazepine SCHEMBL1421962 | 0.84 | LMNA (0.96) | P2RX4LMNATSHRMAPK1SCN4A | |
| Carbamazepine SCHEMBL29023618 | 0.84 | LMNA (0.96) | P2RX4LMNATSHRMAPK1SCN4A | |
| Carbamazepine SCHEMBL29390487 | 0.84 | LMNA (0.96) | P2RX4LMNATSHRMAPK1SCN4A | |
| Carbamazepine SCHEMBL27589204 | 0.84 | LMNA (0.96) | P2RX4LMNATSHRMAPK1SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118954850-A | Method for removing organic pollutants by utilizing metal ion reinforced permanganate oxidation coagulation | 四川大学 | 2024-11-15 | — | — | CN | disclosed |
| US-8569000-B2 | Immunoassays using antibodies specific to carbamazepine | Guangzhou Kingmed Center for Clinical Laboratory (CN) | 2013-10-29 | — | — | US | disclosed |
| US-8569000-B2 | Immunoassays using antibodies specific to carbamazepine | Guangzhou Kingmed Center for Clinical Laboratory (CN) | 2013-10-29 | — | — | US | disclosed |
| US-8563713-B2 | Antibodies specific to carbamazepine | Guangzhou Kingmed Center for Clinical Laboratory (CN) | 2013-10-22 | — | — | US | disclosed |
| US-8563713-B2 | Antibodies specific to carbamazepine | Guangzhou Kingmed Center for Clinical Laboratory (CN) | 2013-10-22 | — | — | US | disclosed |
| US-20120244557-A1 | IMMUNOASSAYS USING ANTIBODIES SPECIFIC TO CARBAMAZEPINE | Guangzhou Kingmed Center for Clinical Laboratory (CN) | 2012-09-27 | — | — | US | disclosed |
| US-20120244557-A1 | IMMUNOASSAYS USING ANTIBODIES SPECIFIC TO CARBAMAZEPINE | Guangzhou Kingmed Center for Clinical Laboratory (CN) | 2012-09-27 | — | — | US | disclosed |
| US-20120244546-A1 | ANTIBODIES SPECIFIC TO CARBAMAZEPINE | Guangzhou Kingmed Center for Clinical Laboratory (CN) | 2012-09-27 | — | — | US | disclosed |
| US-20120244546-A1 | ANTIBODIES SPECIFIC TO CARBAMAZEPINE | Guangzhou Kingmed Center for Clinical Laboratory (CN) | 2012-09-27 | — | — | US | disclosed |
| US-8088918-B2 | Noncardiotoxic pharmaceutical compounds | WILLIAMSBURG HOLDINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088918-B2 | Noncardiotoxic pharmaceutical compounds | WILLIAMSBURG HOLDINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244546-A1 | ANTIBODIES SPECIFIC TO CARBAMAZEPINE | CACNA2D3, CACNA2D4, CACNA2D2 | P2RX4 2361/4885LMNA 4287/4885TSHR 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.